Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool July 21, 2006 Stephen D. Simpson	Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool October 20, 2005 Stephen D. Simpson	Lilly Steady As She Goes In-line performance is probably the best that investors in this pharmaceutical could have hoped for this quarter.
The Motley Fool July 26, 2007 Brian Lawler	Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios.
The Motley Fool January 31, 2007 Brian Lawler	Lilly Floats Atop Rivals The large-cap pharma posts slow, steady growth. Investors, take note.
The Motley Fool April 19, 2011 Brian Orelli	See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff?
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool April 22, 2008 Brian Lawler	Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular.
The Motley Fool January 26, 2005 Stephen D. Simpson	Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool January 29, 2009 Brian Orelli	Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool April 18, 2005 Stephen D. Simpson	Is Lilly About to Bloom? Two new diabetes products could add a little punch to this drug-maker's top line. Lilly shares are not really "cheap" these days, but there's a lot to like about a company with no legal overhang, several new drugs, and a decent dividend yield.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool October 20, 2006 Brian Lawler	Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool July 24, 2007 Brian Orelli	Is Amylin a Two-Hit Wonder? Two drugs, no profitability, but Amylin shares go up on future hopes after the pharmaceutical company reports.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool July 22, 2008 Brian Orelli	Anemic Amylin's Signs of Recovery Sales of Amylin Pharmaceuticals' diabetes drug Byetta have slowed over the last few quarters, but the company seems to be turning things around.
The Motley Fool November 8, 2011 Tim Beyers	Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals?
The Motley Fool November 9, 2011 Brian Orelli	Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it
The Motley Fool May 26, 2011 Brian Orelli	Amylin Scores First in Court But it is still early innings.
Chemistry World July 24, 2013 Andy Extance	Lilly freezes pay as patent cliff looms The company is looking to save money ahead of the imminent expiration of two key patents, from which it faces a 20% fall in revenue.
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
The Motley Fool July 22, 2010 Brian Orelli	It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool April 19, 2004 Alyce Lomax	Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever.
The Motley Fool February 24, 2010 Brian Orelli	A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool April 20, 2006 Stephen D. Simpson	Lilly: Like the Flower, Not the Stock The drug company's doing all right, but the late-stage pipeline isn't that spectacular, and there are better values in the space on both absolute and relative-to-growth bases.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool April 15, 2005 Brian Gorman	Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool April 20, 2009 Brian Orelli	A Cheer and a Boo for Eli Lilly Cost-cutting is nice, but it doesn't slow down the drive toward the patent cliff. Lilly needs to be on the lookout for other partnerships to fill in the upcoming revenue holes.
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
Chemistry World July 3, 2012 Andrew Turley	BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.